CommercialPrior AuthMedium impact
Vestronidase Alfa-vjbk (Mepsevii®)
BCBS Tennessee·TN · Genetics, Pediatrics, Internal Medicine·Medical Policy
Effective date
Oct 31, 2026
We identified it
Aug 13, 2026
Summary
BlueCross BlueShield of Tennessee has issued a new medical policy (effective 10/31/26) establishing coverage criteria for Vestronidase Alfa-vjbk (Mepsevii®) for treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome). The policy requires prior authorization with specific diagnostic testing, clinical documentation, and prescriber specialization requirements. Authorization is limited to 12-month intervals with continuation requiring documented clinical response.
Action Required
By October 31, 2026: Billing and clinical teams must implement the following: (1) Billing team: Configure prior authorization system to require submission of beta-glucuronidase enzyme assay or genetic testing results and baseline clinical documentation for all Mepsevii requests. (2) Clinical staff: Update intake/authorization forms to capture required documentation including uGAG excretion levels (minimum 2-fold over normal for age) and clinical signs/symptoms at baseline. (3) Providers: Ensure only physicians specializing in metabolic disease or lysosomal storage disorders prescribe or consult on Mepsevii therapy; verify prescriber credentials before claim processing. (4) Prior Authorization team: Set authorization duration limit to 12 months per initial approval and continuation. Continuation requests must document clinical response (improvement, stabilization, or slowing of disease progression). (5) All teams: Note that Mepsevii is dosed at 4mg/kg IV every 2 weeks—do not approve claims exceeding this dosing regimen. (6) Compliance: Flag and deny any claims submitted without prior authorization or from non-specialist prescribers, as the policy explicitly requires specialist involvement.